Smallpox vaccine safety is dependent on T cells and not B cells

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1043-1053

  Gordon, Shari N ^a   Cecchinato, Valentina ^a   Andresen, Vibeke ^a   Heraud, Jean Michel ^h   Hryniewicz, Anna ^a   Parks, Robyn Washington ^a   Venzon, David ^b   Chung, Hye Kyung ^f   Karpova, Tatiana ^c   McNally, James ^d,e   Silvera, Peter ^d,e   Reimann, Keith A ^g   Matsui, Hajime ⁱ   Kanehara, Tomomi ⁱ   Shinmura, Yasuhiko ⁱ   Yokote, Hiroyuki ⁱ   Franchini, Genoveffa ^a  

^a Animal Models and Retroviral Vaccines Section   (United States)

^b Biostatistics and Data Management Section   (United States)

^c Fluorescence Imaging Facility   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

^f ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ KAKETSUKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

M T807; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OKT 4; OKT 4A; RITUXIMAB; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; CD20+ B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; DRUG SAFETY; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MONKEYPOX; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGRESSIVE VACCINIA; RHESUS MONKEY; T CELL DEPLETION; T LYMPHOCYTE; VACCINIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CALCIUM-BINDING PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; LYMPHOCYTE DEPLETION; MACACA MULATTA; MONKEYPOX; SKIN; SMALLPOX VACCINE;

EID: 79953309880     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq162     Document Type: Article

References (46)

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Geneva: World Health Organization, 1988.
2. Henderson DA. The looming threat of bioterrorism. Science 1999; 283:1279-82.
3. Bray M, Wright ME. Progressive vaccinia. Clin Infect Dis 2003; 36:766-74. (Pubitemid 36337981)
4. Chen RT, Lane JM. Myocarditis: the unexpected return of smallpox vaccine adverse events. Lancet 2003; 362:1345-6. (Pubitemid 37338332)
5. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37:251-71.
6. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 969; 281:1201-8.
7. Bray M. Pathogenesis of potential antiviral therapy of complications of smallpox vaccination. Antivir Res 2003. In press.
8. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 1975; 55:342-7.
9. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodefi- ciency virus (HIV) disease. N Engl J Med 1987; 316:673-6. (Pubitemid 17032953)
10. Kempe CH. Studies smallpox and complications of smallpox vaccination. Pediatrics 1960; 26:176-89.
11. Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008; 46:1555-61. (Pubitemid 351706737)
12. Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 009; 58:532-6.
13. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culturebased live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008; 17:555-64. (Pubitemid 351578172)
14. Handley L, Buller RM, Frey SE, Bellone C, Parker S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev Vaccines 2009; 8:841-50.
15. Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 2010; 4:71-9.
16. Frey SE, Newman FK, Kennedy JS, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009; 27:1637-44.
17. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 2008; 26:581-8.
18. Beachkofsky TM, Carrizales SC, Bidinger JJ, Hrncir DE, Whittemore DE, Hivnor CM. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch Dermatol 2010; 146:656-61.
19. Artenstein AW, Johnson C, Marbury TC, et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2005; 23:3301-9. (Pubitemid 40523124)
20. Slifka MK. The Future of smallpox vaccination: is MVA the key? Med Immunol 2005; 4:2.
21. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006; 24:7009-22. (Pubitemid 46107176)
22. Hashizume S, Yoshizawa H, Morita M, Suzuki K. Proceedings of the Workshop on vaccinia Viruses as Vectors for vaccine Antigens. 1984; 87-8.
23. Morikawa S, Sakiyama T, Hasegawa H, et al. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol 2005; 79:11873-91. (Pubitemid 41279305)
24. Saijo M, Ami Y, Suzaki Y, et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol 2006; 80:5179-88.
25. Empig C, Kenner JR, Perret-Gentil M, et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 2006; 24:3686-94.
26. Saito T, Fujii T, Kanatani Y, et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009; 301:1025-33.
27. Meseda CA, Mayer AE, Kumar A, et al. Comparative evaluation of the immune response and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin Vaccine Immunol 2009.
28. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2001; 81:1581-600. (Pubitemid 33144422)
29. Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005; 11:740-7. (Pubitemid 41021206)
30. Gordon SN, Weissman AR, Cecchinato V, et al. Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques. J Virol 2010; 84:3043-58.
31. Schmitz JE, Simon MA, Kuroda MJ, et al. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol 1999; 154:1923-32. (Pubitemid 29262876)
32. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003; 12:19-28. (Pubitemid 37321502)
33. Engram JC, Cervasi B, Borghans JA, et al. Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates. Blood 2010; 116:748-58.
34. Edghill-Smith Y, Venzon D, Karpova T, et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis 2003; 188:1181-91. (Pubitemid 37338983)
35. Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 001; 50(RR- 10);1-25.
36. Vaccari M, Mattapallil J, Song K, et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol 2008; 82:9629-38.
37. Karem KL, Reynolds M, Hughes C, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 2007; 14:1318-27. (Pubitemid 350012975)
38. Aragon TJ, Ulrich S, Fernyak S, Rutherford GW. Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968. MC Public Health 2003; 3:26.
39. Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A 2005; 102:4152-7. (Pubitemid 40388571)
40. Freyschmidt EJ, Mathias CB, Diaz N, et al. Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. J Immunol 2010; 185:1295-302.
41. Kawakami Y, Tomimori Y, Yumoto K, et al. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 2009; 206:1219-25.
42. Jensen JR, Sand TT, Jorgensen AS, Thestrup-Pedersen K. Modulation of natural killer cell activity in patients with atopic dermatitis. J Invest Dermatol 1984; 82:30-4.
43. Lever RS, Lesko MJ, Mackie RM, Parrott DM. Natural-killer-cell activity in atopic dermatitis. Clin Allergy 1984; 14:483-90. (Pubitemid 14040353)
44. Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117:176-83. (Pubitemid 43017157)
45. Orihara K, Narita M, Tobe T, et al. Circulating Foxp3+CD4+ cell numbers in atopic patients and healthy control subjects. J Allergy Clin Immunol 2007; 120:960-2. (Pubitemid 47531835)
46. Torreilles SL, Luong RH, Felt SA, McClure DE. Tacrolimus ointment: a novel and effective topical treatment of localized atopic dermatitis in a rhesus macaque (Macaca mulatta). J Am Assoc Lab Anim Sci 2009; 48:307-11.